{"nctId":"NCT00888355","briefTitle":"MK0954 Versus Placebo for Treatment of Mild to Moderate Hypertension","startDateStruct":{"date":"1992-05"},"conditions":["Hypertension"],"count":428,"armGroups":[{"label":"1","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Comparator: placebo"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: losartan potassium"]},{"label":"3","type":"EXPERIMENTAL","interventionNames":["Drug: losartan potassium"]},{"label":"4","type":"EXPERIMENTAL","interventionNames":["Drug: losartan potassium"]}],"interventions":[{"name":"losartan potassium","otherNames":["MK0954"]},{"name":"Comparator: placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient has been diagnosed with mild to moderate hypertension\n* Patient has no treatment or active medical problem, other than hypertension that might affect the patients blood pressure\n\nExclusion Criteria:\n\n* Pregnant of lactating female patients\n* Secondary hypertension or history of malignant hypertension\n* Sitting systolic blood pressure \\> 210 mmHg\n* History of stroke\n* History of myocardial infarction with in the past year\n* Current of prior history of heart failure\n* Known hypersensitivity to losartan\n* Obesity\n* Patients known to be HIV positive or known to be positive for Hepatitis B\n* Absence of one kidney\n* Patient is abusing or previously abused alcohol or drugs with in past two years","healthyVolunteers":false,"sex":"ALL","minimumAge":"21 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12","description":"Mean change from baseline in trough (24 hours after the last morning dose and 12 hours after the last PM dose) SiDBP at Week 12","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","spread":"8.4"},{"groupId":"OG001","value":"-5.8","spread":"6.7"},{"groupId":"OG002","value":"-6.3","spread":"7.4"},{"groupId":"OG003","value":"-8.0","spread":"7.9"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) as Week 12","description":"Mean change from baseline in trough (24 hours after the last morning dose and 12 hours after the last PM dose) SiSBP at Week 12","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"15.1"},{"groupId":"OG001","value":"-7.2","spread":"13.9"},{"groupId":"OG002","value":"-7.6","spread":"12.6"},{"groupId":"OG003","value":"-8.8","spread":"13.0"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Peak Sitting Diastolic Blood Pressure (SiDBP) at Week 12","description":"Mean change from baseline in peak (6 hours after the last morning dose) SiDBP at Week 12","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.0","spread":"9.7"},{"groupId":"OG001","value":"-7.7","spread":"8.5"},{"groupId":"OG002","value":"-8.7","spread":"8.1"},{"groupId":"OG003","value":"-9.9","spread":"9.5"}]}]}]},{"type":"SECONDARY","title":"Categories of Antihypertensive Response in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12","description":"Patients with trough SiDBP \\<90 mm Hg were in Category I, ≥90 but decreased at least 10 mm Hg were in Category II, and ≥90 and decreased less than 10 mm Hg or increased were in Category III.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"26","spread":null},{"groupId":"OG003","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"14","spread":null},{"groupId":"OG003","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null},{"groupId":"OG001","value":"68","spread":null},{"groupId":"OG002","value":"61","spread":null},{"groupId":"OG003","value":"53","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Patients With Clinical Adverse Experiences (CAEs)","description":"An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"59","spread":null},{"groupId":"OG002","value":"59","spread":null},{"groupId":"OG003","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"49","spread":null},{"groupId":"OG002","value":"47","spread":null},{"groupId":"OG003","value":"46","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Patients With Serious CAEs","description":"Serious CAEs are any AEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"104","spread":null},{"groupId":"OG001","value":"107","spread":null},{"groupId":"OG002","value":"105","spread":null},{"groupId":"OG003","value":"103","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Patients With Drug-related CAEs","description":"Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) CAEs during the 12-week treatment period","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"21","spread":null},{"groupId":"OG003","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"96","spread":null},{"groupId":"OG002","value":"85","spread":null},{"groupId":"OG003","value":"90","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Patients Discontinued Due to CAEs","description":"Patients discontinued due to CAEs during the 12-week treatment period","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"108","spread":null},{"groupId":"OG002","value":"105","spread":null},{"groupId":"OG003","value":"103","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Patients Who Died","description":"Patients who died during the 12-week treatment period","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"106","spread":null},{"groupId":"OG001","value":"108","spread":null},{"groupId":"OG002","value":"106","spread":null},{"groupId":"OG003","value":"105","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Patients With Laboratory Adverse Experiences (LAEs)","description":"A laboratory adverse experience (LAE) is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null},{"groupId":"OG001","value":"98","spread":null},{"groupId":"OG002","value":"96","spread":null},{"groupId":"OG003","value":"100","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Patients With Serious LAEs","description":"Serious LAEs are any LAEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"104","spread":null},{"groupId":"OG001","value":"105","spread":null},{"groupId":"OG002","value":"103","spread":null},{"groupId":"OG003","value":"104","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Patients With Drug-related LAEs","description":"Patients with drug-related LAEs during the 12-week treatment period","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"99","spread":null},{"groupId":"OG003","value":"104","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Patients Discontinued Due to LAEs","description":"Patients discontinued due to LAEs during the 12-week treatment period","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"104","spread":null},{"groupId":"OG001","value":"105","spread":null},{"groupId":"OG002","value":"101","spread":null},{"groupId":"OG003","value":"104","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":null,"commonTop":[]}}}